Prevalence of antibiotic resistance in US hospitals

Edelsberg, John; Weycker, Derek; Barron, Rich; Li, Xiaoyan; Wu, Hongsheng; Oster, Gerry; Badre, Sejal; Langeberg, Wendy J.; Weber, David J.

doi:10.1016/j.diagmicrobio.2013.11.011

Cited by 94 publications

(62 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unmeasured reasons that physicians may choose clindamycin include (1) a mistaken belief that it is adequate coverage for MRSA, 15 (2) its simple dosing compared to antibiotics that must be adjusted in renal and hepatic impairment, (3) its ease of transition to oral regimens, and (4) its lack of monitoring requirements, as is needed for vancomycin. If SCIP or other quality guidelines are to be adopted for head and neck surgery, these data and data from previous trials suggest that the ASHP-recommended ampicillin/sulbactam and cefazolin 1 metronidazole are good candidates.…”

Section: Discussionmentioning

confidence: 99%

Laryngectomy Complications Are Associated with Perioperative Antibiotic Choice

Langerman

Ham

Pisano

et al. 2015

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

There is substantial variability in perioperative antibiotic strategies for laryngectomy. Clindamycin was associated with much higher odds of short-term complications as compared to other common regimens. Based on these data, clinical trials should be planned to firmly establish the most effective and cost-effective antibiotic management for laryngectomy and determine potential alternatives to clindamycin for penicillin-allergic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Laryngectomy Complications Are Associated with Perioperative Antibiotic Choice

Langerman

Ham

Pisano

et al. 2015

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…La creciente (cualitativa y cuantitativamente) resistencia a la ceftriaxona y la cefixima, que junto con la previa y ya asentada a las fluoroquinolonas, complica mucho el tratamiento de la gonorrea 17,18 . Es preocupante el elevado porcentaje de resistencia a la vancomicina en Enterococcus faecium, una bacteria ya naturalmente multirresistente, en la que además empieza a aparecer resistencia a la daptomicina y al linezolid 19 , lo que puede conducir en algún caso a una ausencia total de antibióticos eficaces. La Organización Mundial de la Salud ha informado un aumento del 650% de los casos de tuberculosis multirresistente en África entre 2005 y 2012 20 .…”

Section: Los Hechosunclassified

Resistencia bacteriana a los antibióticos: una crisis global

Alós

2015

Enfermedades Infecciosas y Microbiología Clínica

143

View full text Add to dashboard Cite

“…Reports of DAP-nonsusceptible enterococcal strains, defined as an MIC of Ͼ4 g/ml, are becoming more prevalent, however (16). Recent data from a single center demonstrate that up to 0.5% of E. faecalis and 4.7% of E. faecium strains possess DAP MICs of 4 g/ml (17). At these MICs, mutations that confer DAP inactivity are more prevalent than at lower MIC values, necessitating caution when treating these isolates (18).…”

mentioning

confidence: 99%

β-Lactams Enhance Daptomycin Activity against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models

Smith

Barber

Raut

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Enterococcus faecalis and Enterococcus faecium are frequently resistant to vancomycin and ␤-lactams. In enterococcal infections with reduced glycopeptide susceptibility, combination therapy is often administered. Our objective was to conduct pharmacokinetic/pharmacodynamic (PK/PD) models to evaluate ␤-lactam synergy with daptomycin (DAP) against resistant enterococci. One E. faecalis strain (R6981) and two E. faecium strains (R6370 and 8019) were evaluated. DAP MICs were obtained. All strains were evaluated for response to LL37, an antimicrobial peptide, in the presence and absence of ceftaroline (CPT), ertapenem (ERT), and ampicillin (AMP). After 96 h, in vitro models were run simulating 10 mg DAP/kg body weight/day, 600 mg CPT every 8 h (q8h), 2 g AMP q4h, and 1 g ERT q24h, both alone and in combination against all strains. DAP MICs were 2, 4, and 4 g/ml for strains R6981, R6370, and 8019, respectively. PK/PD models demonstrated bactericidal activity with DAP-CPT, DAP-AMP, and DAP-ERT combinations against strain 8019 (P < 0.001 and log 10 CFU/ml reduction of >2 compared to any single agent). Against strains R6981 and R6370, the DAP-AMP combination demonstrated enhancement against R6370 but not R6981, while the combinations of DAP-CPT and DAP-ERT were bactericidal, demonstrated enhancement, and were statistically superior to all other regimens at 96 h (P < 0.001) against both strains. CPT, ERT, and AMP similarly augmented LL37 killing against strain 8019. In strains R6981 and R6370, CPT and ERT aided LL37 more than AMP (P < 0.001). Compared to DAP alone, combination regimens provide better killing and prevent resistance. Clinical research involving DAP combinations is warranted. Enterococcus faecalis and Enterococcus faecium together account for 12% of hospital-acquired infections in the United States (1). Often, enterococcal infections are caused by multidrug-resistant strains. For example, 0.4 to 5.2% and 70 to 92.6% of E. faecalis and E. faecium strains are resistant to ampicillin, respectively, and vancomycin resistance is present in up to 12.5% of E. faecalis and 79.7% of E. faecium (2-4). Vancomycin-resistant enterococci (VRE) are associated with increased mortality and complicated infections, such as infective endocarditis (5). Treatment of VRE infections can prove problematic, as available treatment options are potentially limited by static activity and/or platelet suppression with long-term use (6-8). Daptomycin (DAP) is a bactericidal lipopeptide often used against resistant enterococci (9). Mechanistically, it binds with calcium to form a cationic moiety that disrupts membrane potential to confer its antimicrobial effects, similar to endogenous, cationic antimicrobial peptides (10, 11). DAP is frequently dosed at 6 mg/kg body weight daily, although recent clinical and in vitro data suggest improved efficacy at higher doses (7,(12)(13)(14). DAP retains excellent in vitro activity against E. faecalis and E. faecium, with MIC 50/90 values of 1/2 and 2/4 g/ml, respectively (15). Reports of DAP-nonsuscept...

show abstract

Prevalence of antibiotic resistance in US hospitals

Cited by 94 publications

References 19 publications

Laryngectomy Complications Are Associated with Perioperative Antibiotic Choice

Laryngectomy Complications Are Associated with Perioperative Antibiotic Choice

Resistencia bacteriana a los antibióticos: una crisis global

β-Lactams Enhance Daptomycin Activity against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models

Contact Info

Product

Resources

About